Welcome to our dedicated page for ProMIS Neurosciences news (Ticker: $PMN), a resource for investors and traders seeking the latest updates and insights on ProMIS Neurosciences stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ProMIS Neurosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ProMIS Neurosciences's position in the market.
Rhea-AI Summary
ProMIS Neurosciences Inc. (Nasdaq: PMN) announced the publication of study results in Acta Neuropathologica Communications supporting the targeting of RACK1 as a potential therapeutic approach for Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Lobar Degeneration (FTLD). The study identifies RACK1 as a novel misfolded protein target for ALS and FTLD, providing another target for the company's pipeline as they advance clinical development of their lead product, PMN310, for Alzheimer’s disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.68%
Tags
-
Rhea-AI Summary
ProMIS Neurosciences Inc. (Nasdaq: PMN) has initiated a first-in-human Phase 1a clinical trial of PMN310, a novel monoclonal antibody designed to be highly selective for toxic oligomers of amyloid-beta (Aβ), which are believed to be a major driver of Alzheimer’s disease (AD). The Company aims to develop better therapeutics for neurodegenerative diseases, leveraging recent results from a third-party clinical study to potentially differentiate PMN310 from other available treatments. The Phase 1a study will enroll up to five cohorts of eight adult healthy volunteers, with initial safety and pharmacokinetic (PK) data expected to be shared in the first half of 2024. Subsequent Phase 1b study in patients with Mild Cognitive Impairment (MCI) due to AD and patients with mild AD will be facilitated by the Phase 1a results, providing important insights into the safety profile of PMN310.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.67%
Tags
-
Rhea-AI Summary
ProMIS Neurosciences Inc. (Nasdaq: PMN) raised $20.4 million in PIPE gross proceeds to support the development of PMN310 and novel antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases. The company also provided an update on their clinical and corporate initiatives, including the dosing of the first subjects in a Phase 1a clinical trial of PMN310 for Alzheimer’s disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.09%
Tags
Rhea-AI Summary
ProMIS Neurosciences closes PIPE financing, raising approximately $20.4 million for clinical development and general expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
-
News
Rhea-AI Summary
ProMIS Neurosciences to present at H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.74%
Tags
-
Rhea-AI Summary
ProMIS Neurosciences announces a $20.4 million fundraise through a private investment in public equity (PIPE) financing
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.75%
Tags
Rhea-AI Summary
ProMIS Neurosciences announced compelling preclinical data supporting the therapeutic potential of PMN310 for Alzheimer's disease (AD) and the promise of a computationally derived AD vaccine candidate. PMN310 received FDA clearance for its IND application and plans to initiate a Phase 1a clinical trial. The company also presented positive preclinical data demonstrating greater selectivity of PMN310 for toxic amyloid-beta oligomers, indicating improved safety profile and clinical benefit. ProMIS continues to advance its amyloid-beta vaccine program for AD prevention. Financially, the company reported a decrease in cash and cash equivalents, lower research and development expenses, and an increase in general and administrative expenses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.33%
Tags
-
Rhea-AI Summary
ProMIS Neurosciences Inc. presented preclinical data at the Alzheimer's Association International Conference (AAIC) 2023. The data highlighted the potential therapeutic advantage of their lead candidate for Alzheimer's disease (AD), PMN310, which targets toxic amyloid-beta oligomers (AβO) more selectively than other antibodies. They also presented preclinical mouse studies on a computationally-derived AD vaccine targeting AβO.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
120.28%
Tags
-
Rhea-AI Summary
ProMIS Neurosciences Inc. has completed its continuance from the Canada Business Corporations Act into the Province of Ontario. The Continuance was approved by the Corporation's shareholders with a 97.7% majority. The shift is expected to facilitate internal management functions and will not impact operations. The Company will continue to operate with its headquarters in Toronto and research laboratories in British Columbia and its US office in Cambridge, MA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.07%
Tags
Rhea-AI Summary
ProMIS Neurosciences Inc. has announced its voluntary delisting from the Toronto Stock Exchange (TSX) and consolidation of trading on the Nasdaq exchange. The delisting will not affect the company's listing on the Nasdaq, and shares will continue to trade uninterrupted under the symbol 'PMN'. The company believes that delisting from the TSX will lower expenses and provide savings in time and effort for management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.11%
Tags
ProMIS Neurosciences, Inc.
Nasdaq:PMN
PMN Rankings
PMN Stock Data
30.15M
10.81M
24.35%
17.71%
0.13%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
United States of America
TORONTO
About PMN
promis™ neurosciences, inc. (tse: pmn, https://ca.finance.yahoo.com/q/bc?s=pmn.to), is a development stage biotech company that discovers and develops precision therapeutics and companion diagnostics for early detection and effective treatment of neurodegenerative diseases, in particular alzheimer’s disease (ad) and amyotrophic lateral sclerosis (als). the company’s scientific foundation centers on the growing knowledge base relating to diseases characterized by the presence of abnormal, misfolded proteins. several neurodegenerative diseases exhibit protein misfolding, such as ad, als, and parkinson’s disease (pd). recent published evidence indicates that for a given misfolded protein there exist multiple prion-like strains, each strain representing a specific target against which specific therapeutics can be developed. the company is focused on the discovery and development of precision therapeutics and companion diagnostics to combat the several strains of beta-amyloid (aβ) and tau i